Evidence map›Paper›PMID 31534913›Full record

ArticleAfrican journal of laboratory medicine2019

Blueprint for building a biorepository in a resource-limited setting that follows international best practices.

Alash'le G Abimiku, Talishea Croxton, Petronilla J Ozumba, Ndidi Agala, Olasinbo Balogun, Emmanuel Jonathan, Enzenwa Onyemata, Kachimi Ndifon, Sunji Nadoma, Thankgod Anazodo and 2 more

Abstract read
In one paragraph

Article in African journal of laboratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alash'le G AbimikuInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-2213-0204
Talishea CroxtonInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-3095-3817
Petronilla J OzumbaInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-8243-9647
Ndidi AgalaInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-2814-8651
Olasinbo BalogunInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-9411-2983
Emmanuel JonathanInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-6284-8849
Enzenwa OnyemataInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-8566-5444
Kachimi NdifonInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-4994-905X
Sunji NadomaInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-6968-0700
Thankgod AnazodoInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-0050-3751
Sam PetersInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-5883-1200
Christine M BeiswangerCoriell Institute for Medical Research, Camden, New Jersey, United States.ORCID https://orcid.org/0000-0003-3162-568X

Funding

IHVN H3 Africa Biorepository InitiativeUH3HG007008 · NHGRI · INSTITUTE OF HUMAN VIROLOGY · PI ABIMIKU, ALASH'LE G. · 2015 to 2018
$2.9M
Institute of Human Virology H3Africa Biorepository (I-HAB) ADMIN SUPPLEMENTU24HG007008 · NHGRI · INSTITUTE OF HUMAN VIROLOGY · PI ABIMIKU, ALASH'LE G. · 2019 to 2022
$2.3M
IHVN H3 Africa Biorepository InitiativeUH2HG007008 · NHGRI · INSTITUTE OF HUMAN VIROLOGY · PI ABIMIKU, ALASH'LE G. · 2012 to 2014
$811k
NHGRI NIH HHS U24 HG007008NHGRI NIH HHS UH2 HG007008NHGRI NIH HHS UH3 HG007008
6 · The paper itself

Abstract

backgroundGenetic diversity is abundant on the African continent. However, genomic research has been hampered by a lack of high quality and extensively annotated biospecimens and the necessary infrastructure to support such a technology-intensive effort.

objectiveThe Institute of Human Virology Nigeria (IHVN) partnered with the H3Africa Consortium and the Coriell Institute for Medical Research to build an internationally recognised biorepository for the receipt, processing, storage and distribution of biospecimens for biomedical research. Here, the authors describe the procedures, challenges and results encountered.

resultsKey requirements for a high-quality biorepository were identified: (1) institutional support of infrastructure and services, (2) on-site trained staff with primary commitment to the biorepository, (3) reliance on best practices from globally recognised biorepository groups, (4) early implementation of a quality management system, (5) adoption of a laboratory information management system with demonstrated versatility in functions, (6) collaboration with external experts and sharing of experience through abstracts, newsletters, published manuscripts, and attendance at meetings and workshops, (7) strict adherence to local and national ethical standards and (8) a sustainability plan that is reviewed and updated annually.

conclusionUtilising published best practices of globally recognised experts in the biorepository field as a benchmark, IHVN expanded and reorganised its existing laboratory facility and staff to take on this new purpose.

Indexed as

best practicesbiobankbiorepositorydeveloping countryinternational guidelines

Identifiers

PMID31534913
PMCPMC6739520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.